Home
Amylin Pharmaceuticals

Amylin Pharmaceuticals Market Share Analysis for June 2026

astrazeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Health > Biotechnology and Pharmaceuticals

Domainamylin.com

Year Founded1987

Employees1001 - 5000

Annual Revenue$200M - $500M

Amylin Pharmaceuticals

Amylin Pharmaceuticals (including company regionals)

amylin.com

See more website traffic and engagement information

Amylin Pharmaceuticals Revenue up to June 2026 is 200M - 500M

revenue generated by Amylin Pharmaceuticals top domains

Amylin Pharmaceuticals top domains revenue over 3 years

Revenue for Amylin Pharmaceuticals top domains

amylin.com200M - 500M

See more with Sales Intelligence

Total visits to Amylin Pharmaceuticals's top domains

Understand Amylin Pharmaceuticals market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Amylin Pharmaceuticals's top domains

Analyze Amylin Pharmaceuticals engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Amylin Pharmaceuticals's top domains

See how Amylin Pharmaceuticals keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Amylin Pharmaceuticals top competitors by domain

Top similar sites in June 2026, ranked by their affinity

amgen.comCompany NameAmgenEmployees> 10001HQUnited States, California, Thousand OaksAnnual revenue> $1BTotal visits638.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Amylin Pharmaceuticals

These are the website technologies, by industry, used by Amylin Pharmaceuticals top domains

Conversion & Analytics (3)

Google Analytics

Mobile (2)

Meta Viewport

Payment & Currencies (2)

Euro

Social (2)

Instagram

More Technologies

2

See all

News & Signals from Amylin Pharmaceuticals

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAmylin is developing exenatide.Amylin Pharmaceuticals initiated the development of a synthetic form of exendin-4, later named exenatide.

NewsBristol-Myers Squibb Co acquired Amylin for $7B on Jan 1st '12.Dr. Jonathan Rothbard, CannBioRx's Chief Scientific Officer, was involved in establishing Amylin Pharmaceuticals, which was acquired by Bristol-Myers Squibb in 2012 for $7 billion.